Aarey Drugs (India) Performance
| AAREYDRUGS | 59.74 1.57 2.70% |
The firm shows a Beta (market volatility) of 0.74, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, Aarey Drugs' returns are expected to increase less than the market. However, during the bear market, the loss of holding Aarey Drugs is expected to be smaller as well. At this point, Aarey Drugs Pharmace has a negative expected return of -0.25%. Please make sure to confirm Aarey Drugs' total risk alpha, kurtosis, as well as the relationship between the Kurtosis and market facilitation index , to decide if Aarey Drugs Pharmace performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Aarey Drugs Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. Even with unfluctuating performance in the last few months, the Stock's basic indicators remain relatively invariable which may send shares a bit higher in January 2025. The latest agitation may also be a sign of long-running up-swing for the enterprise retail investors. ...more
1 | Aarey Drugs Pharmaceuticals Ltds Stock Surges to 52-Week High, Outperforming Sector - MarketsMojo | 09/05/2024 |
2 | Aarey Drugs Standalone September 2024 Net Sales at Rs 105.14 crore, up 81.81 percent Y-o-Y - Moneycontrol | 11/21/2024 |
| Begin Period Cash Flow | 7.1 M |
Aarey |
Aarey Drugs Relative Risk vs. Return Landscape
If you would invest 7,126 in Aarey Drugs Pharmaceuticals on September 2, 2024 and sell it today you would lose (1,152) from holding Aarey Drugs Pharmaceuticals or give up 16.17% of portfolio value over 90 days. Aarey Drugs Pharmaceuticals is generating negative expected returns and assumes 2.3187% volatility on return distribution over the 90 days horizon. Simply put, 20% of stocks are less volatile than Aarey, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Aarey Drugs Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Aarey Drugs' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Aarey Drugs Pharmaceuticals, and traders can use it to determine the average amount a Aarey Drugs' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1073
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | AAREYDRUGS |
Estimated Market Risk
| 2.32 actual daily | 20 80% of assets are more volatile |
Expected Return
| -0.25 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.11 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Aarey Drugs is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Aarey Drugs by adding Aarey Drugs to a well-diversified portfolio.
Aarey Drugs Fundamentals Growth
Aarey Stock prices reflect investors' perceptions of the future prospects and financial health of Aarey Drugs, and Aarey Drugs fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Aarey Stock performance.
| Return On Equity | 0.0374 | ||||
| Return On Asset | 0.0058 | ||||
| Profit Margin | 0.01 % | ||||
| Operating Margin | 0.01 % | ||||
| Current Valuation | 2.08 B | ||||
| Shares Outstanding | 28.35 M | ||||
| Price To Book | 1.25 X | ||||
| Price To Sales | 0.36 X | ||||
| Revenue | 3.96 B | ||||
| Gross Profit | 207.6 M | ||||
| EBITDA | 114.16 M | ||||
| Net Income | 46.84 M | ||||
| Total Debt | 313.52 M | ||||
| Book Value Per Share | 47.33 X | ||||
| Cash Flow From Operations | (29.94 M) | ||||
| Earnings Per Share | 2.26 X | ||||
| Total Asset | 3.03 B | ||||
| Retained Earnings | 531.08 M | ||||
About Aarey Drugs Performance
Assessing Aarey Drugs' fundamental ratios provides investors with valuable insights into Aarey Drugs' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Aarey Drugs is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Aarey Drugs is entity of India. It is traded as Stock on NSE exchange.Things to note about Aarey Drugs Pharmace performance evaluation
Checking the ongoing alerts about Aarey Drugs for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Aarey Drugs Pharmace help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Aarey Drugs Pharmace generated a negative expected return over the last 90 days | |
| Aarey Drugs generates negative cash flow from operations | |
| About 51.0% of the company shares are held by company insiders | |
| Latest headline from news.google.com: Aarey Drugs Standalone September 2024 Net Sales at Rs 105.14 crore, up 81.81 percent Y-o-Y - Moneycontrol |
- Analyzing Aarey Drugs' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Aarey Drugs' stock is overvalued or undervalued compared to its peers.
- Examining Aarey Drugs' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Aarey Drugs' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Aarey Drugs' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Aarey Drugs' stock. These opinions can provide insight into Aarey Drugs' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Aarey Stock Analysis
When running Aarey Drugs' price analysis, check to measure Aarey Drugs' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aarey Drugs is operating at the current time. Most of Aarey Drugs' value examination focuses on studying past and present price action to predict the probability of Aarey Drugs' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aarey Drugs' price. Additionally, you may evaluate how the addition of Aarey Drugs to your portfolios can decrease your overall portfolio volatility.